MGTX: Margin operasi MeiraGTx Holdings plc

Logo grafis MeiraGTx Holdings plc (MGTX)

The current operating margin of MeiraGTx Holdings plc (MGTX) is based on the stable operation of its own gene therapy manufacturing plants. The 44.50 metric captures the value of this parameter, demonstrating effective cost management. The development of MeiraGTx Holdings plc (MGTX) relies on correcting genetic defects to treat blindness, while its financial stability depends on clinical trial outcomes and capital expenditure control.

meiragtx.com (MGTX): Rentabilitas dodolan miturut bathi operasi saka 04.07.2022 nganti 20.11.2026

MGTX (MeiraGTx): rincian analitis lan laporan miturut indikator

Pambiji fundamental perusahaan:MGTX, MeiraGTx
Barang utama meiragtx.com

MeiraGTx Holdings plc (MGTX) is developing a high-tech gene therapy segment characterized by significant capital expenditures. Costs associated with environmental safety and reagent disposal directly impact the calculated remaining funds from sales. The operating margin measures the share of earnings before interest and taxes, reflecting the efficiency of core process management. Low values here often signal an expansion phase. By analyzing the operating margin, an investor performs a real-time assessment of the business's profitability.

Karo sapa MeiraGTx Holdings plc saingan

Margin dodolan operasi TEM|QGEN - Tingkat bathi adhedhasar bathi operasi|Margin operasi IONS|RGEN - Rentabilitas dodolan operasi|Rentabilitas operasi Avidity RNA|Margin operasi CRISPR Therapeutics Corp CRSP|GeneDx Corp - Margin operasi|Ultragenyx Pharma (RARE) - Margin dodolan operasi|beamtx.com (BEAM) - Rentabilitas operasi|SRPT: Rasio bathi operasi|Margin dodolan operasi TWST|TXG - Tingkat bathi adhedhasar bathi operasi|Margin operasi NTLA|Rentabilitas kegiatan operasi Stoke Therapeutics|Rentabilitas operasi BioLife Solutions BLFS|Wave Life Sciences (WVE) - Rentabilitas dodolan operasi|Maze Therapeutics, Inc. - Margin operasi|Rentabilitas kegiatan operasi Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Rentabilitas operasi|TSHA: Rasio bathi operasi|Rentabilitas operasi uniQure Pharma|Rentabilitas dodolan operasi REGENXBIO Inc. RGNX|Rentabilitas operasi Solid Biosciences (SLDB)|Ocugen Corp - Rentabilitas dodolan miturut bathi operasi|Rentabilitas operasi Pacific Biosciences PACB|Rasio bathi operasi BNTC (Benitec)|Design Corp - Margin operasi|Rocket Pharmaceuticals - Rasio bathi operasi|Rentabilitas dodolan miturut bathi operasi 4D Molecular Therapeutics, Inc.|Rentabilitas dodolan operasi Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Margin operasi|Rentabilitas dodolan operasi Editas EDIT|Margin operasi SLN|ProQR Therapeutics - Rentabilitas dodolan miturut bathi operasi|Margin operasi CDXS (Codexis, Inc.)|SGMO: Rentabilitas dodolan miturut bathi operasi|Nautilus Biotechnology - Margin operasi|Tingkat bathi operasi MGX (Metagenomi, Inc)|DTIL: Margin operasi|GBIO: Rasio bathi operasi|Rentabilitas operasi Boundless Bio Inc.|Margin dodolan operasi Exicure (XCUR)|Margin operasi IMNN|PHIO (Phio Pharmaceuticals Corp.) - Tingkat bathi operasi|Mustang Bio, Inc. - Margin dodolan operasi|RNAZ - Margin dodolan operasi|BNGO: Margin dodolan operasi|APDN (Applied DNA Sciences Inc) - Rentabilitas dodolan miturut bathi operasi|BLUE (Bluebird Bio) - Margin dodolan operasi|ImmunoPrecise Antibodies Ltd - Tingkat bathi operasi|OMGA (Omega Therapeutics Inc) - Margin operasi|Rentabilitas operasi OMIC|Rentabilitas operasi Regulus Therapeutics Inc. (RGLS)|Margin dodolan operasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Margin dodolan operasi|Tingkat bathi operasi TCON|UBX - Rentabilitas operasi